Summary
Signal counts
Assets tracked: 9
Watchlist assets: 7
Registry stop assets: 2
Sponsor overview
Hoffmann-La Roche
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT02846428 | https://clinicaltrials.gov/study/NCT01399684 | https://clinicaltrials.gov/study/NCT02951767 | https://clinicaltrials.gov/study/NCT07239245 | https://clinicaltrials.gov/study/NCT05908786 | https://clinicaltrials.gov/study/NCT04321330 | https://clinicaltrials.gov/study/NCT05312671 | https://clinicaltrials.gov/study/NCT04462276 | https://clinicaltrials.gov/study/NCT03513952 | https://clinicaltrials.gov/study/NCT02924883 | https://clinicaltrials.gov/study/NCT03206203 | https://clinicaltrials.gov/study/NCT03548428 | https://clinicaltrials.gov/study/NCT05535244 | https://clinicaltrials.gov/study/NCT03625141 | https://clinicaltrials.gov/study/NCT02322814 | https://clinicaltrials.gov/study/NCT02230306 | https://clinicaltrials.gov/study/NCT02650401 | https://clinicaltrials.gov/study/NCT01378962 | https://clinicaltrials.gov/study/NCT04802759 | https://clinicaltrials.gov/study/NCT05805501 | https://clinicaltrials.gov/study/NCT00977379
Assets
Linked programs
- 5-Fluorouracil: Results Not Found Signal (3/5)
- Atezolizumab: Operational Burden Signal (4/5)
- Cevostamab: Operational Burden Signal (2/5)
- Cobimetinib: Registry Stop Signal (4/5)
- Entrectinib: Low Signal (1/5)
- erlotinib: Low Signal (1/5)
- Giredestrant: Operational Burden Signal (2/5)
- Tobemstomig: Watchlist Signal (2/5)
- WBRT: Registry Stop Signal (3/5)